From the Phase II study of a selective FLT3 inhibitor AC220, Ambit Biosciences and Astellas Pharma have reported positive clinical results which is used to treat acute myeloid leukaemia.

The open-label, single-arm and multi-centre study evaluated AC220 as an oral, once-a-day, monotherapy treatment in 240 patients with FLT3-ITD activating mutations who had relapsed or are refractory to second-line chemotherapy.

The findings from the study demonstrated improvement in complete remission rate, clinical response and safety profile in patients treated with the drug candidate.

Common treatment-related adverse events observed included nausea, vomiting, fatigue and febrile neutropenia.